These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 33720878)
1. Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. Rezaei M; Sadeghi M; Korourian A; Tabarsi P; Porabdollah M; Askari E; Mortaz E; Mahmoudi S; Marjani M; Velayati AA Hum Antibodies; 2021; 29(2):109-113. PubMed ID: 33720878 [TBL] [Abstract][Full Text] [Related]
2. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033 [TBL] [Abstract][Full Text] [Related]
3. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152 [TBL] [Abstract][Full Text] [Related]
4. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients. Yang L; Xu Q; Yang B; Li J; Dong R; Da J; Ye Z; Xu Y; Zhou H; Zhang X; Liu L; Zha Y; Yu F BMC Microbiol; 2021 Dec; 21(1):351. PubMed ID: 34922455 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19. Flinck H; Rauhio A; Luukinen B; Lehtimäki T; Haapala AM; Seiskari T; Aittoniemi J Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115197. PubMed ID: 32977117 [TBL] [Abstract][Full Text] [Related]
6. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. Favresse J; Cadrobbi J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J J Med Virol; 2021 Apr; 93(4):2262-2269. PubMed ID: 33200836 [TBL] [Abstract][Full Text] [Related]
7. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population. Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay. Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654 [TBL] [Abstract][Full Text] [Related]
9. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan. Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990 [TBL] [Abstract][Full Text] [Related]
10. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L Front Immunol; 2021; 12():723585. PubMed ID: 34489974 [TBL] [Abstract][Full Text] [Related]
11. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698 [TBL] [Abstract][Full Text] [Related]
12. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. Lumley SF; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Jeffery K; Eyre DW; N Engl J Med; 2021 Feb; 384(6):533-540. PubMed ID: 33369366 [TBL] [Abstract][Full Text] [Related]
13. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Emmerich P; Murawski C; Ehmen C; von Possel R; Pekarek N; Oestereich L; Duraffour S; Pahlmann M; Struck N; Eibach D; Krumkamp R; Amuasi J; Maiga-Ascofaré O; Rakotozandrindrainy R; Asogun D; Ighodalo Y; Kann S; May J; Tannich E; Deschermeier C Trop Med Int Health; 2021 Jun; 26(6):621-631. PubMed ID: 33666297 [TBL] [Abstract][Full Text] [Related]
14. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Fenwick C; Croxatto A; Coste AT; Pojer F; André C; Pellaton C; Farina A; Campos J; Hacker D; Lau K; Bosch BJ; Gonseth Nussle S; Bochud M; D'Acremont V; Trono D; Greub G; Pantaleo G J Virol; 2021 Jan; 95(3):. PubMed ID: 33144321 [TBL] [Abstract][Full Text] [Related]
15. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. De Marco Verissimo C; O'Brien C; López Corrales J; Dorey A; Cwiklinski K; Lalor R; Doyle JM; Field S; Masterson C; Ribes Martinez E; Hughes G; Bergin C; Walshe K; McNicholas B; Laffey JG; Dalton JP; Kerr C; Doyle S Epidemiol Infect; 2021 Jun; 149():e140. PubMed ID: 34099081 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828 [TBL] [Abstract][Full Text] [Related]
17. Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection. Portilho AI; Silva VO; Ahagon CM; Matsuda EM; de Oliveira EL; da Silveira EPR; de Souza Lima AK; Lindoso JAL; de Campos IB; Hong MA; De Gaspari E; de Macedo Brígido LF J Med Virol; 2022 Jan; 94(1):178-185. PubMed ID: 34428312 [TBL] [Abstract][Full Text] [Related]
18. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. Kowitdamrong E; Puthanakit T; Jantarabenjakul W; Prompetchara E; Suchartlikitwong P; Putcharoen O; Hirankarn N PLoS One; 2020; 15(10):e0240502. PubMed ID: 33035234 [TBL] [Abstract][Full Text] [Related]
19. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. Masiá M; Fernández-González M; Telenti G; Agulló V; García JA; Padilla S; García-Abellán J; Galiana A; Gonzalo-Jiménez N; Gutiérrez F J Autoimmun; 2021 Sep; 123():102703. PubMed ID: 34303083 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]